Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases-Reference-Cited by-同舟云学术

Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases

Published:2021-11 Issue: Volume:100 Page:108044
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Li Zhaoyang,Dumas Todd,Seth Berry N.,McCoy Barbara,Yel Leman

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference21 articles.

1. Primary immunodeficiency, Allergy Asthma;McCusker;Clin. Immunol.,2018

2. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee;Tangye;J. Clin. Immunol.,2019

3. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again;Wasserman;J. Clin. Immunol.,2012

4. CUVITRU, Immune Globulin Subcutaneous (Human), 20% Solution [prescribing information], Baxalta US Inc., Lexington, MA, 2019.

5. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies;Berger;Clin. Immunol.,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose–exposure–efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy;Annals of Clinical and Translational Neurology;2024-07-08

2. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies;International Immunopharmacology;2024-02

3. Subcutaneous immunoglobulin 20% (Ig20Gly) treatment regimens in pediatric patients with primary immunodeficiencies – real-world data from the IG TATRY study;Expert Review of Clinical Immunology;2023-07-25

4. Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies;International Immunopharmacology;2022-12

5. Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases;International Immunopharmacology;2022-03